MS MBA - LakeShore Biopharma Interim Director
| LSBPW Stock | 0.04 0 2.83% |
Director
MS MBA is Interim Director of LakeShore Biopharma Co,
| Age | 49 |
| Phone | 86 10 8920 2086 |
| Web | https://www.ysbiopharm.com |
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Nobuyuki Hirano | Morgan Stanley | 69 | |
| Ognjen Redzic | Assurant | 50 | |
| Paul Reilly | Assurant | 64 | |
| Juan Cento | Assurant | 69 | |
| Dennis Nally | Morgan Stanley | 68 | |
| Judith Miscik | Morgan Stanley | 62 | |
| Alistair Darling | Morgan Stanley | 66 | |
| Julie Schneekloth | United Fire Group | N/A | |
| Debra Perry | Assurant | 69 | |
| Elizabeth Corley | Morgan Stanley | 64 | |
| Mary Schapiro | Morgan Stanley | 65 | |
| Thomas Glocer | Morgan Stanley | 61 | |
| Gregory Ziegler | Cincinnati Financial | N/A | |
| Rayford Wilkins | Morgan Stanley | 69 | |
| Robert Herz | Morgan Stanley | 67 | |
| Lawrence Jackson | Assurant | 67 | |
| Paget Alves | Assurant | 66 | |
| Robert Stein | Assurant | 72 | |
| JeanPaul Montupet | Assurant | 73 | |
| Harriet Edelman | Assurant | 65 | |
| Hutham Olayan | Morgan Stanley | 65 | |
LakeShore Biopharma Co, Leadership Team
Elected by the shareholders, the LakeShore Biopharma's board of directors comprises two types of representatives: LakeShore Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LakeShore. The board's role is to monitor LakeShore Biopharma's management team and ensure that shareholders' interests are well served. LakeShore Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LakeShore Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dave Chenn, CoCEO Board | ||
| CFA MBA, President Officer | ||
| Yuan Liu, Head Research | ||
| MS MBA, Interim Director | ||
| Zenaida MD, Chief Officer | ||
| Gang Li, Head Sales | ||
| Zhiyuan Ran, Head Department | ||
| Wang Xu, Chief Officer |
LakeShore Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LakeShore Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Revenue | 573.42 M | ||||
| EBITDA | (368.66 M) | ||||
| Net Income | (433.46 M) | ||||
| Total Debt | 424.46 M | ||||
| Cash Flow From Operations | (295.23 M) | ||||
| Number Of Employees | 758 | ||||
| Total Asset | 1.51 B | ||||
| Retained Earnings | (2.31 B) | ||||
| Working Capital | 100.94 M | ||||
| Net Asset | 1.51 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for LakeShore Stock Analysis
When running LakeShore Biopharma's price analysis, check to measure LakeShore Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LakeShore Biopharma is operating at the current time. Most of LakeShore Biopharma's value examination focuses on studying past and present price action to predict the probability of LakeShore Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LakeShore Biopharma's price. Additionally, you may evaluate how the addition of LakeShore Biopharma to your portfolios can decrease your overall portfolio volatility.